Avery Nathanson, MD
Sleep Medicine · Decatur, GANPI 1679574198
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,916 and has fallen 99.2% since, to $16 in 2025.
Across 307 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$950
- Boehringer Ingelheim$495
- Jazz Pharmaceuticals Inc.$407
- Harmony Biosciences LLC$330
- Insmed, Inc.$323
- plus $3K from 30 others
Across 10 payments — averaging $6533.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$48K
- Boehringer Ingelheim$18K
What the payments were for
- Food & beverage$6,03496%
- Education$2284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,033 |
| GSK | 50 | $950 |
| Boehringer Ingelheim | 24 | $495 |
| Jazz Pharmaceuticals Inc. | 14 | $407 |
| Harmony Biosciences LLC | 17 | $330 |
| Insmed, Inc. | 12 | $323 |
| Regeneron Healthcare Solutions, Inc. | 13 | $290 |
| Sanofi | 13 | $290 |
| Genentech USA, Inc. | 11 | $213 |
| Inspire Medical Systems, Inc. | 4 | $187 |
| Mylan Specialty L.p. | 11 | $184 |
| Grifols USA, LLC | 10 | $181 |
| Amgen | 7 | $146 |
| Actelion Pharmaceuticals US, Inc. | 7 | $130 |
| Paratek Pharmaceuticals, Inc. | 6 | $127 |
| Novartis | 5 | $95 |
| Circassia Inc. | 6 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Sunovion Pharmaceuticals Inc. | 6 | $76 |
| Mallinckrodt Enterprises LLC | 3 | $71 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Merck | 4 | $67 |
| Mallinckrodt Hospital Products Inc. | 2 | $55 |
| Shire North American Group Inc | 2 | $48 |
| Advanced Respiratory, Inc | 2 | $42 |
| Baxter Healthcare | 2 | $42 |
| Philips North America LLC | 2 | $41 |
| Pulmonx Corporation | 2 | $41 |
| Electromed, Inc. | 2 | $31 |
| Phadia US Inc. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| ZOLL Respicardia, Inc. | 1 | $16 |
| Resmed Corp | 1 | $15 |
| Inogen, Inc. | 1 | $11 |
How this compares
$6,262 in reported general payments places this provider in the 75th percentile of 50 sleep medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 311 | $267,870 |
| OfevNintedanib Esylate | 11 | $145,586 |
| NucalaMepolizumab | 23 | $92,574 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $59,671 |
| Arnuity ElliptaFluticasone Furoate | 236 | $58,361 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $56,111 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 79 | $46,802 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $37,447 |
| Spiriva RespimatTiotropium Bromide | 42 | $25,484 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $17,793 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,638 |
| EliquisApixaban | 12 | $7,476 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 58 | $7,191 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 276 | $6,704 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $950 | $543,071804 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Striverdi Respimat | $495 | $211,783124 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $1,033 | $61,39582 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 sleep medicine providers in Georgia.
Other sleep medicine in Decatur
- Mark PollockDecatur$3K
- Ee Rah SungDecatur$18
- Murad AssaadAtlanta$139K
- Nancy CollopAtlanta$28K
- Scott LeibowitzAtlanta$22K
- Anuj ChandraTrenton$20K
- Chantale BransonAtlanta$17K
- Melissa RhodesCartersville$14K
- James DalySavannah$12K
- Romy HoqueAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.